Tag: neurology clinical trials market trends

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Neurology Clinical Trials Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for clinical trials in neurology has experienced robust expansion lately, projected to increase from $5.8 billion in 2025 to $6.21 billion in 2026, exhibiting a compound annual growth rate of 7.0%. This historical expansion was fueled by several factors, including the increasing incidence of neurological disorders, the burgeoning research pipelines in the pharmaceutical sector, augmented investments in the development of neurological drugs, the deployment of sophisticated imaging technologies, and a greater engagement in clinical research activities.

The market for neurology clinical trials is poised for substantial expansion, projecting a valuation of $8.05 billion by 2030, driven by a compound annual growth rate of 6.7%. This anticipated surge in the upcoming years can be ascribed to several key factors, including the escalating application of artificial intelligence in analyzing trial data, a heightened need for accelerated trial completion, the broader implementation of patient-focused trial methodologies, the increasing integration of remote patient monitoring systems, and a more concentrated effort on addressing rare neurological disorders. Furthermore, significant trends expected to shape this market during the forecast period involve a greater embrace of adaptive clinical trial methodologies, a rise in the utilization of digital tools for patient oversight, a heightened focus on clinical trials for neurological conditions centered around specific biomarkers, the expansion of decentralized clinical trial frameworks, and an augmented emphasis on gathering real-world evidence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Neurology Clinical Trials Market Demand Drivers: What Is Fueling Industry Growth?

The expanding incidence of neurological conditions is poised to be a significant catalyst for the advancement of the neurology clinical trials sector. These disorders, which impact the brain, spinal cord, or nerves and disrupt the nervous system’s typical operations, are on the rise, largely attributed to an aging global demographic. As individuals grow older, they become more vulnerable to age-related ailments like Alzheimer’s and Parkinson’s disease. Clinical trials in neurology play a crucial role in addressing these disorders by evaluating novel therapies, pharmaceuticals, and interventions aimed at refining diagnostic accuracy, managing symptoms effectively, potentially mitigating disease advancement, and ultimately improving patient prognoses. To illustrate this trend, projections from the Australian Institute of Health and Welfare in September 2024 indicated that the number of individuals in Australia experiencing dementia is anticipated to more than double, escalating from 411,100 in 2023 to an estimated 849,300 by 2058, with a projected 315,500 men and 533,800 women to be affected during that period. Consequently, the growing prevalence of neurological disorders directly fuels the expansion of the neurology clinical trials market.

Neurology Clinical Trials Market Segment Analysis: What Are The Major Market Categories?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

Neurology Clinical Trials Market Innovation Trends: Which Developments Are Transforming The Industry?

The neurology clinical trials sector is characterized by key players committed to advancing cutting-edge treatments, including monoclonal antibodies, designed to precisely interact with neurological pathways, thereby enhancing therapeutic outcomes and expediting the advent of new medical interventions. A monoclonal antibody, essentially a manufactured protein designed for the specific identification and attachment to particular antigens or proteins, serves as a highly targeted tool in both therapeutic applications and diagnostic procedures for addressing disease processes. Illustrating this, in July of 2024, Eli Lilly and Company, a prominent American pharmaceutical entity, introduced Kisunla (donanemab-azbt), a treatment indicated for individuals experiencing the initial symptomatic stages of Alzheimer’s disease. This medication is designed to mitigate the decline in cognitive and functional abilities, affording qualifying patients extended periods of autonomy and active engagement in their daily routines. Its mechanism involves the targeting and reduction of amyloid plaques within the brain, and clinical studies have demonstrated that it can decelerate the progression of the disease by as much as 35% when compared to a placebo in individuals with less advanced stages of the condition.

Neurology Clinical Trials Market Leading Companies Driving Competitive Growth

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Access The Complete Neurology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Neurology Clinical Trials Market Largest Region By Revenue And Market Share

North Americawas the largest region in the neurology clinical trials market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Neurology Clinical Trials Market Over The Forecast Period?

The neurology clinical trials market size has experienced significant growth in recent years. It is anticipated to increase from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by several factors, including a rise in the prevalence of neurological diseases, the enlargement of pharmaceutical research pipelines, heightened investment in neurology drug development, the availability of sophisticated imaging tools, and an uptick in participation in clinical research.

The neurology clinical trials market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a value of $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the forecast period include the increasing adoption of AI-driven trial analytics, a heightened demand for more rapid trial execution, the broadening of patient-centric trial models, greater integration of remote monitoring technologies, and an amplified focus on rare neurological conditions. Key trends anticipated in the forecast period encompass a rising embrace of adaptive clinical trial designs, the increased utilization of digital patient monitoring tools, an evolving emphasis on biomarker-based neurology trials, the expansion of decentralized clinical trial models, and a stronger focus on generating real-world evidence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Growth Drivers Are Expected To Support The Neurology Clinical Trials Market Forward?

The increasing incidence of neurological disorders is projected to drive the expansion of the neurology clinical trials market. Neurological disorders are defined as conditions impacting the brain, spinal cord, or nerves, thereby disrupting the nervous system’s normal functioning. The rise in these disorders is primarily linked to an aging demographic, as older individuals are more susceptible to age-related conditions like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a vital role in tackling neurological disorders by assessing new treatments, drugs, or interventions to improve diagnostic methods, control symptoms, slow disease advancement, and enhance patient outcomes. For instance, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that the number of Australians affected by dementia is anticipated to more than double, climbing from 411,100 in 2023 to 849,300 by 2058. Additionally, by 2058, roughly 315,500 men and 533,800 women are expected to be living with dementia. Therefore, the growing prevalence of neurological disorders is a key factor propelling the growth of the neurology clinical trials market.

Which Segment-Based Categories Are Covered In The Neurology Clinical Trials Market?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

What Trends Are Influencing The Neurology Clinical Trials Market?

Major companies operating in the neurological disorder diagnostics market are prioritizing the development of innovative solutions, such as neurological disease quantification software, to assist one billion individuals affected by neurological diseases worldwide. Neurological disease quantification software serves as a tool for measuring and analyzing brain function and the advancement of disease in neurological conditions. As an illustration, in January 2024, Quibim, a Spain-based biotechnology company, launched QP-Brain, an AI-based early-stage neurological disease quantification software. QP-Brain by Quibim is advanced neuroimaging analysis software specifically designed to quantify brain tissue alterations in neurological diseases. Its distinct capabilities include AI-powered automated segmentation and detailed volumetric analysis, providing precise insights into brain structure changes for both clinical and research applications.

Which Organizations Are Involved In The Neurology Clinical Trials Market?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Access The Complete Neurology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Which Area Represents The Largest Portion Of The Neurology Clinical Trials Market?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurology Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=25847&type=smp

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Interventional Neurology Devices And Equipment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Neurology Clinical Trials Market Projected To Reach By 2030?

The neurology clinical trials market has experienced substantial growth in recent years. It is projected to expand from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the past can be attributed to the rising prevalence of neurological diseases, the broadening of pharmaceutical research pipelines, increased investment in the development of neurology drugs, the accessibility of advanced imaging tools, and a surge in participation in clinical research.

The neurology clinical trials market size is anticipated to undergo significant growth in the upcoming years. It is projected to expand to $8.05 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period is propelled by the enhanced utilization of AI-driven trial analytics, an escalated demand for quicker trial execution, the proliferation of patient-centric trial models, augmented integration of remote monitoring technologies, and a heightened emphasis on rare neurological conditions. Major trends for the forecast period encompass a greater uptake of adaptive clinical trial designs, increased application of digital patient monitoring tools, a deepening focus on biomarker-based neurology trials, the continued expansion of decentralized clinical trial models, and a strong emphasis on generating real-world evidence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Primary Drivers Are Impacting The Neurology Clinical Trials Market Growth?

The growth of the neurology clinical trials market is projected to be propelled by the escalating occurrence of neurological disorders. These conditions involve the brain, spinal cord, or nerves, thereby disrupting the nervous system’s regular function. The rise in neurological disorders is mainly attributed to the aging demographic, as older adults are more prone to age-related ailments like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a vital role in managing neurological disorders by testing new treatments, drugs, or interventions designed to enhance diagnosis, alleviate symptoms, slow down disease progression, and improve patient results. For example, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, projected that the population of Australians afflicted with dementia is anticipated to more than double, increasing from 411,100 in 2023 to 849,300 by 2058. Furthermore, by 2058, an estimated 315,500 men and 533,800 women are expected to be living with dementia. Consequently, the increasing prevalence of neurological disorders is a primary driver for the expansion of the neurology clinical trials market.

Which Segment Classifications Are Used In The Neurology Clinical Trials Market Segment Analysis?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

Which Trends Are Shaping Growth In The Neurology Clinical Trials Market?

Leading firms within the neurology clinical trials market are concentrating on creating advanced solutions, particularly monoclonal antibodies, aiming to precisely address neurological pathways, enhance treatment effectiveness, and speed up the creation of new therapeutic options. A monoclonal antibody, by definition, is a laboratory-created molecule specifically designed to identify and attach to particular proteins or antigens, frequently employed for its high precision in targeting disease mechanisms within both therapeutic and diagnostic applications. Illustratively, in July 2024, Eli Lilly and Company, a pharmaceutical firm based in the U.S., introduced Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer’s disease. This medication is designed to decelerate cognitive and functional deterioration, thereby providing eligible patients with an extended period of independence and participation in their daily routines. It operates by targeting and diminishing brain amyloid plaques; clinical studies have indicated up to a 35% reduction in disease advancement compared to a placebo for individuals with less severe forms of the condition.

Which Firms Are Contributing To The Neurology Clinical Trials Market Ecosystem?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Get The Full Neurology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Which Region Dominates The Neurology Clinical Trials Market By Market Share?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurology Clinical Trials Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Market Report

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Market Report

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Neurology Clinical Trials Market From 2026 To 2030?

The neurology clinical trials market has experienced strong expansion in recent years. It is projected to grow from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historic period is due to factors such as an increase in neurological disease prevalence, the expansion of pharmaceutical research pipelines, greater investment in neurology drug development, the availability of advanced imaging tools, and rising participation in clinical research.

The neurology clinical trials market size is projected for substantial expansion in the coming years. This market is set to reach $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during this period stems from factors such as the increasing application of AI-driven trial analytics, a growing need for quicker trial execution, the proliferation of patient-centric trial models, greater incorporation of remote monitoring technologies, and an enhanced focus on uncommon neurological conditions. Key developments anticipated in the forecast period encompass the wider embrace of adaptive clinical trial designs, increased utilization of digital tools for patient monitoring, a sharpened emphasis on biomarker-driven neurology trials, the broadening of decentralized clinical trial frameworks, and a heightened significance placed on generating real-world evidence.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Neurology Clinical Trials Market?

The rising incidence of neurological conditions is projected to boost the neurology clinical trials market in the future. Neurological disorders are health issues that impact the brain, spinal cord, or nerves, thus disrupting the normal functioning of the nervous system. The primary reason for the rise in these disorders is the aging demographic, as elderly individuals are more prone to age-related ailments like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a crucial role in addressing neurological disorders by evaluating novel treatments, medications, or interventions to enhance diagnosis, alleviate symptoms, decelerate disease progression, and improve patient results. For example, data from September 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government body, indicates that the population of Australians suffering from dementia is anticipated to more than double, climbing from 411,100 in 2023 to 849,300 by 2058. Furthermore, by 2058, it is estimated that 315,500 men and 533,800 women will be affected by dementia. Consequently, the increasing occurrence of neurological disorders is propelling the expansion of the neurology clinical trials market.

Which Segments Are Included In The Analysis Of The Neurology Clinical Trials Market?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

What Trends Are Advancing Progress In The Neurology Clinical Trials Market?

Major companies active within the neurology clinical trials market are concentrating on developing innovative solutions, including monoclonal antibodies, aimed at specific neurological pathways to enhance treatment efficacy and expedite the creation of novel therapies. A monoclonal antibody refers to a molecule produced in a laboratory, engineered to identify and bind to particular proteins or antigens, commonly utilized to precisely target disease mechanisms in treatments and diagnostics. For instance, in July 2024, Eli Lilly and Company, a pharmaceutical company based in the U.S., launched Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer’s disease. This treatment works to slow cognitive and functional decline, thereby giving eligible patients more time to sustain independence and participate in daily life. It operates by targeting and reducing brain amyloid plaques, and clinical trials have indicated up to a 35% slowing of disease progression against placebo in those with less advanced forms of the disease.

Which Key Industry Participants Are Active In The Neurology Clinical Trials Market?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Read the full neurology clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

What Are The Leading Geographic Regions In The Neurology Clinical Trials Market?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurology Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25847&type=smp

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Interventional Neurology Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurology clinical trials market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Neurology Clinical Trials Market reach by 2030 starting from 2026 levels?

The neurology clinical trials market size has exhibited robust growth over recent years. It is projected to increase from $5.8 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. This historical growth stems from factors such as an escalation in neurological disease prevalence, the broadening of pharmaceutical research pipelines, increased capital allocated to neurology drug development, the accessibility of advanced imaging tools, and a greater involvement in clinical research.

The neurology clinical trials market is projected for significant expansion over the coming years, reaching a valuation of $8.05 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is primarily fueled by several factors, including the expanding application of AI-driven trial analytics, a heightened demand for swifter trial execution, the broader adoption of patient-centric trial models, the increasing incorporation of remote monitoring technologies, and a sharper focus on uncommon neurological conditions. Key trends anticipated within this period encompass the growing acceptance of adaptive clinical trial designs, the increased deployment of digital patient monitoring tools, an escalating emphasis on biomarker-based neurology trials, the wider implementation of decentralized clinical trial models, and an intensified focus on generating real-world evidence.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Drivers Are Influencing Long-Term Growth In The Neurology Clinical Trials Market?

A rise in neurological disorder cases is anticipated to drive the expansion of the neurology clinical trials market in the coming years. These disorders are defined as ailments impacting the brain, spinal cord, or nerves, thereby hindering the nervous system’s regular operation. The primary cause of this increase is the aging demographic, given that seniors are more prone to age-associated illnesses like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a crucial role in addressing neurological disorders through the evaluation of novel treatments, medications, or therapeutic approaches aimed at enhancing diagnosis, alleviating symptoms, delaying disease progression, and bettering patient results. For example, data from September 2024 by the Australian Institute of Health and Welfare, an Australia-based government body, projects that the population of Australians afflicted with dementia will more than double, escalating from 411,100 in 2023 to 849,300 by 2058. Furthermore, by 2058, an estimated 315,500 men and 533,800 women are expected to be living with dementia. Consequently, the expanding occurrence of neurological conditions is fueling the growth of the neurology clinical trials market.

How Is The Neurology Clinical Trials Market Divided Into Segments?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

What Trends Are Driving The Growth Trajectory Of The Neurology Clinical Trials Market?

Leading companies active in the neurology clinical trials market are concentrating on developing innovative solutions, such as monoclonal antibodies, to target specific neurological pathways, enhance treatment efficacy, and accelerate the creation of new therapies. A monoclonal antibody is a laboratory-produced molecule engineered to recognize and bind to specific proteins or antigens, frequently utilized to precisely target disease mechanisms in treatments and diagnostics. For instance, in July 2024, Eli Lilly and Company, a U.S.-based pharmaceutical company, launched Kisunla (donanemab-azbt) for treating early symptomatic Alzheimer’s disease. This treatment works to slow cognitive and functional decline, enabling eligible patients more time to maintain independence and engage in daily life. It specifically targets and reduces brain amyloid plaques, with clinical trials indicating up to a 35% slowing of disease progression compared to a placebo in individuals with less advanced disease.

Which Major Firms Are Strengthening Their Position In The Neurology Clinical Trials Market?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Neurology Clinical Trials Market?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurology Clinical Trials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25847&type=smp

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Pediatric Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-clinical-trials-global-market-report

Clinical Trial Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-imaging-global-market-report

Nephrologists Market Report 2020 2030 Covid 19 Implications And Growth 2026

https://www.thebusinessresearchcompany.com/report/nephrologists-market-global-report-2020-2030-covid-19-implications-and-growth

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model